| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyluridine does not have a defined biological target as it is a protected nucleoside building block. Its purpose is to serve as a protected nucleoside for RNA synthesis and nucleoside modification. The compound is a uridine analog, and uridine has potential antiepileptic effects.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, this compound is used as a building block for RNA synthesis and nucleoside modification. The 2'-O-methyl modification enhances the stability and properties of RNA molecules. The DMT protecting group at the 5'-position allows for selective deprotection and further functionalization.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a protected nucleoside building block rather than a bioactive molecule. RNA molecules synthesized using this nucleoside can be delivered into cells for various functional studies. The 2'-O-methyl modification enhances the metabolic stability of RNA in cellular environments.
|
| Enzyme Assay |
The standard procedure for using this compound involves its incorporation into RNA sequences during solid-phase synthesis. The DMT-protected nucleoside is converted to the phosphoramidite form and coupled to the growing RNA chain using standard phosphoramidite chemistry. Following chain assembly, the DMT group is removed, and the RNA is deprotected.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to this protected nucleoside as it is a chemical building block. RNA molecules synthesized using this nucleoside can be evaluated in cell culture experiments. Typical protocols include transfection of modified RNA into mammalian cell lines and assessment of RNA stability, translation efficiency, and functional effects.
|
| Animal Protocol |
This compound is not administered to animals as it is a chemical building block for RNA synthesis. RNA molecules synthesized using this nucleoside may be evaluated in animal models for therapeutic applications. Typical studies involve administration of modified RNA to mice or rats via various routes.
|
| ADME/Pharmacokinetics |
As a chemical building block, this compound does not have established pharmacokinetic properties. RNA molecules containing 2'-O-methyl modifications exhibit enhanced metabolic stability compared to unmodified RNA. The pharmacokinetic profile depends on the overall RNA sequence, length, and additional modifications.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent. RNA molecules containing 2'-O-methyl modifications generally exhibit improved safety profiles.
|
| References | |
| Additional Infomation |
5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyluridine is a research-grade chemical used for RNA synthesis and nucleoside modification. It is not an approved pharmaceutical and has no clinical trial history. The compound is typically stored at -20°C under desiccated conditions. This product is for research use only and is not for human therapeutic applications.
|
| Molecular Formula |
C31H32N2O8
|
|---|---|
| Molecular Weight |
560.59
|
| Exact Mass |
560.216
|
| CAS # |
103285-22-9
|
| PubChem CID |
11039002
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
2.835
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
41
|
| Complexity |
884
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CO[C@@H]1[C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)COC(C3=CC=CC=C3)(C4=CC=C(C=C4)OC)C5=CC=C(C=C5)OC)O
|
| InChi Key |
MFDHAVFJDSRPKC-YXINZVNLSA-N
|
| InChi Code |
InChI=1S/C31H32N2O8/c1-37-23-13-9-21(10-14-23)31(20-7-5-4-6-8-20,22-11-15-24(38-2)16-12-22)40-19-25-27(35)28(39-3)29(41-25)33-18-17-26(34)32-30(33)36/h4-18,25,27-29,35H,19H2,1-3H3,(H,32,34,36)/t25-,27-,28-,29-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7838 mL | 8.9192 mL | 17.8383 mL | |
| 5 mM | 0.3568 mL | 1.7838 mL | 3.5677 mL | |
| 10 mM | 0.1784 mL | 0.8919 mL | 1.7838 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
